Aarhus University Seal / Aarhus Universitets segl

Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-Year Nationwide Study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


AIM: Over the last two decades, guidelines for the treatment of type 2 diabetes have changed considerably. In the same time-period, a number of novel glucose-lowering drugs have been introduced. Our aim was to examine the nationwide trends in antidiabetic utilization and expenditure in Denmark over the past twenty-two years.

METHODS: Data on antidiabetic use and expenditure from 1996 to 2017 was retrieved from the Register of Medicinal Product Statistics. Antidiabetic use was reported as defined daily dose (DDD) in total counts and per 1000 inhabitants/day. Expenditure was reported as volume sold in total counts per 1000 inhabitants and as annual mean expenditure.

RESULTS: Throughout the study period, total use of antidiabetic drugs increased from 16.4 to 55.8 DDD per 1000 inhabitants/day while total expenditure increased from €59 million to €286 million. The introduction of glucagon-like peptide-1 receptor analogues, dipeptidyl peptidase-4 inhibitors and sodium-glucose transport protein 2 inhibitors has since 2005 led to considerable variation in the proportional use of the different drug classes. Insulin and insulin analogues accounted for the majority of the cost for antidiabetic drugs peaking at 75% in 2008. However, its proportional impact on overall antidiabetic drug expenditure decreased to ~44% in 2017. In contrast, a steep increase in glucagon-like peptide-1 receptor analogue expenditure was observed from 2010 to 2017, reaching an annual cost of €85 million (~29% of all antidiabetic expenditure).

CONCLUSION: Antidiabetic utilization and cost in Denmark has increased considerably over the last twenty-two years in accordance with the increased incidence of type 2 diabetes and change in treatment guidelines. The release of several novel antidiabetic drugs seems to be responsible for the increase in antidiabetic expenditure. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Pages (from-to)167-172
Number of pages6
Publication statusPublished - Feb 2020

    Research areas

  • antidiabetic drug, cost-effectiveness, database research, health economics, pharmaco-economics, pharmaco-epidemiology

See relations at Aarhus University Citationformats

ID: 167624851